Key Points
- Director Alan Ezekowitz sold 81,820 shares for about $3.93 million, reducing his Septerna holdings by 69.68% to 35,600 shares.
- Septerna reported a quarterly loss of $0.57 per share, worse than analysts’ $0.42 loss estimate; revenue of $18.88 million also fell short of expectations.
- Analysts’ average rating was Moderate Buy, with an average price target of $56.44. Shares were trading at $42.60 in Friday’s session.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) Director Alan Ezekowitz sold 81,820 shares of the firm's stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $48.09, for a total transaction of $3,934,723.80. Following the completion of the sale, the director owned 35,600 shares in the company, valued at $1,712,004. The trade was a 69.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Septerna Price Performance
Shares of Septerna stock traded up $0.74 during trading on Friday, hitting $42.60. 337,791 shares of the stock were exchanged, compared to its average volume of 421,986. Septerna, Inc. has a 12-month low of $19.69 and a 12-month high of $53.34. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -33.02 and a beta of 2.20. The firm's 50-day moving average price is $40.46 and its 200 day moving average price is $33.12.
Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.15). The business had revenue of $18.88 million for the quarter, compared to analysts' expectations of $20.78 million. Septerna had a negative return on equity of 14.98% and a negative net margin of 61.29%. As a group, research analysts forecast that Septerna, Inc. will post -1.45 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. JonesTrading raised their target price on Septerna from $43.00 to $62.00 and gave the stock a "buy" rating in a research report on Thursday, August 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Septerna in a research note on Thursday, October 15th. JPMorgan Chase & Co. upped their price target on Septerna from $38.00 to $48.00 and gave the company an "overweight" rating in a report on Wednesday, August 19th. Raymond James Financial reiterated a "strong-buy" rating and issued a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company increased their price target on shares of Septerna from $50.00 to $61.00 and gave the company an "overweight" rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Septerna currently has an average rating of "Moderate Buy" and an average target price of $56.44.
View Our Latest Research Report on Septerna
Institutional Investors Weigh In On Septerna
Several hedge funds and other institutional investors have recently bought and sold shares of SEPN. Covestor Ltd increased its position in Septerna by 19.0% during the third quarter. Covestor Ltd now owns 2,526 shares of the company's stock worth $98,000 after buying an additional 403 shares during the period. Sterling Capital Management LLC lifted its stake in Septerna by 215.0% in the third quarter. Sterling Capital Management LLC now owns 630 shares of the company's stock valued at $25,000 after buying an additional 430 shares during the last quarter. Engineers Gate Manager LP lifted its stake in Septerna by 5.0% in the second quarter. Engineers Gate Manager LP now owns 17,350 shares of the company's stock valued at $581,000 after buying an additional 822 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Septerna by 12.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,117 shares of the company's stock valued at $474,000 after acquiring an additional 1,343 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Septerna in the third quarter valued at approximately $93,000.
Latest Septerna News
These are some of the SEPN news items that stood out recently:
About Septerna
(
Get Free Report)
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
